BIIB113 is an oral small-molecule inhibitor of OGA intended to reduce the progression of tau pathology through increased tau O-GlcNAcylation and attenuated aggregation [18], which is hypothesized to slow the cognitive decline seen in AD [5]. This evidence concerns the gene MAPT and Alzheimer disease.